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Abstract: 
Rosuvastatin calcium [RSV] specifically inhibit the enzyme 3-hydroxy-3-methylglutaryl-Co-enzyme A [HMG-CoA] 
reductase. It belongs to family of cholesterol lowering medications which are denoted as statins and useful in 
treatment of dyslipidemia where it helps in reducing the chances of arthrosclerosis development by decreasing the 
level of bad cholesterol and hence eliminating the possibilities of heart diseases. RSV was developed by Astra-Zeneca 
and it was granted approval in 2003 by US-FDA. This article presents a literature review on hyphenated analytical 
techniques implemented for the estimation of RSV in pharmaceutical preparations and biological fluids. 
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INTRODUCTION: 
Illinois University in the 1950s led to innovation of 3-
hydroxy-3-methylglutaryl-CoA [HMG CoA] by the 
investigators Bimal Kumar Bachhawat and Minor J. 
Coon, similarly recognized as β-Hydroxy β-
methylglutaryl-CoA, which is a transitional in the 
ketogenesis and mevalonate pathways. It is made 
by acetoacetyl CoA and acetyl CoA from HMG-CoA 
synthase[1,2].HMG-CoA is a transitional metabolic in 
the metabolism of the amino acid chain, isoleucine, 
leucine and valine are included[3]. Its immediate 
precursors are β-hydroxy β-methylbutyryl-CoA 
[HMB-CoA] and β-methylglutaconyl-CoA [MG-
CoA], produces mevalonic acid from HMG-CoA[4-6]. 
The reductase of HMG-CoA is a cholesterol 
biosynthesis measurement step. Statins specifically 
constrain the enzyme 3-hydroxy-3-methylglutaryl - 
coenzyme A [HMG - CoA], thus preventing the 
reduction of cholesterol in cardiovascular events[7].In 
pharmacokinetics and drug interaction studies, the 
development of analytical methods for the measuring 
of statins in biological fluids is a key determinant[8]. 
To produce reliable pharmacokinetic records, it is 
essential to use fine - categorized and completely 
authorized analytical methods. For the quantitation of 
each HMG-CoA reductase inhibitor, several analytical 
methods have also been developed in pharmaceutical 
formulations, which are crucial during the process of 
quality control of pharmaceutical products. In 
addition, analytical methods have been developed for 
the quantification of mevalonate acid to be used as a 
biomarker for statin inhibition of the enzyme. Statins 
specifically inhibit the enzyme 3-hydroxy-3-
methylglutaryl-coenzyme A [HMG-CoA] hence 
prevention of cardiovascular events due to the 
cholesterol reduction[9-12]. 
 
The purpose of this review is to provide an overview 
of relevant published literature and to discuss methods 
for determining RSV alone or in mixtures, in pure 
form, formulations and biological samples using the 
analytical procedure LC – MS / MS. 
 
ROSUVASTATIN CHEMISTRY: 
 RSV is a synthetic compound produced as 
monocalcium bis [+]-7-[4-[4-fluorophenyl]-6-
isopropyl-2-[N-methylN-
methansulfonylaminopyrimidine]-5-yl]-[3R, 5S]-
dihydroxy-[E]-6 heptenoate[13,14]. RSV 
configuration comprises on its own enantiomer [3R, 
5S], expressed 
and administered as the active hydroxy acid calcium 
salt[15]. The chemical formula is C44H54Ca 
F2N6O12S2 and molecular weight is 1001.141 g/mol 
RSV is a white amorphous powder that is sparingly 
soluble in methanol [MeOH] and water and slightly 
soluble in ethanol [EtOH][14,16]. The pharmacophore 
consists of a portion of dihydroxy heptenoic acid, 
which binds the target enzyme HMGCoA reductase to 
the active position[17]. Differently from other statins, 
the addition of a stable polar methane sulfonamide 
group in the RSV structure confers relatively low 
lipophilicity[17,18]. The log D [distribution of the 
drug into octanol: water] measured at pH 7.4 is -0.33, 
which is comparable to pravastatin and lower than 
other statins [atorvastatin, fluvastatin, simvastatin, and 
cerivastatin][18]. The commercial formulations of 
RSV tablets available contain 5, 10, 20, or 40 mg of 
RSV[16]. 
 
PHARMACODYNAMICS, EFFICACY, AND 
SAFETY: 
RSV showing effects on lipid profile by inhibiting 3-
hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] 
reductase, a limiting enzyme in cholesterol 
biosynthesis that liable for conversion of HMG-CoA 
to mevalonate. RSV is a competitive inhibitor of 
HMG-CoA reductase, having a chemical structure 
very similar to HMG portion of HMG-CoA. Olsson et 
al.[19] have reported that a dosage of RSV starting 1 
to 80 mg above 6 weeks has given rise to in LDL - C 
reductions ranging from 34 percent to 65 percent. 
There are some reports have been published on 
effectiveness of RSV over the other statins on 
reduction of LDL-C[20-22] and it shows that RSV is 
more effective than other statins in increasing HDL-C 
and lowering LDL-C at same dose[23]. RSV can be 
administered along with other drugs to for better 
management of high-risk patients whose cholesterol 
level cannot be controlled with RSV 
monotherapy[24]. In literature it is reported that, RSV 
showing the adverse effect such as myalgia, 
myopathy, rhabdomyolysis and acute liver 
injury[25,26].  
 
PHARMACOKINETICS: 
RSV oral bioavailability is about 20 percent and pea 
plasma concentration [Cmax] is reached 3-5 hours 
after 10-80 mg oral dose is given[27]. Cmax and area 
under the plasma concentration-time curve [AUC] 
increase proportionally to the dose. RSV 
administration with food decreased the ratio of drug 
absorption by 20 percent as assessed by Cmax; 
however the extent of absorption is not affected when 
measured by AUC[28,29]. The average volume of 
distribution at steady state of RSV is approximately 
134 L. RSV is 88% bound to plasma proteins, mainly 
albumin. RSV undergoes minimal metabolism with 
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approximately 10% of radio- labeled dose recovered 
as metabolite [30-33]. RSV recovery is primarily 
through fecal elimination route with about 72% of 
absorbed RSV being eliminated through bile secretion 
and 28% through renal excretion. The half-life of the 
circulating plasma is about 20 hours [34]. No effects 
on RSV pharmacokinetics were observed with 
deference to age, sex, or daytime [morning or evening] 
of administration[35,36].  
 
LIQUID CHROMATOGRAPHY-MASS 
SPECTROMETRY METHODS: 
Liquid Chromatography / Mass Spectrometry 
[LC/MS] is rapidly becoming liquid 
chromatographers' preferred tool. It's a powerful 
technique of analysis combining the solving power of 
LC with mass spectrometry detection specificity[37-
39]. Sample components are separated by LC and then 
introduced to the MS. The MS creates charged ions 
and detects them.  The LC / MS data can be used to 
deliver information about specific sample components 
' molecular weight, identity, structure and 
quantity[40]. LC-MS/MS method is the most explored 
technique for quantitative analysis of RSV alone or in 
mixture. 
 
Table 1[41-60] express the LC-MS/MS technique for 
RSV analysis alone or in mixture with other drugs 
determined in biological fluids. Most LC-MS/MS 
analyses were performed in +ve ion mode [ESI+] for 
the quantification of RSV in human plasma. LC-
MS/MS methods were performed with a C18 
analytical column and the mobile phase was composed 
by MeOH or ACN as organic solvent and water with 
volatile additives including acetate and formic acid, 
which were added to enhance ionization and increase 
the method's sensitivity. Multiple reaction monitoring 
[MRM] was the most commonly used method and the 
selected [MRM] precursor 
ion was [M+H+] at m / z 482.RSV can be detected in 
both +ve and -ve ionization modes of a mass 
spectrometer, since its structure contains a pyrimidine 
ring and a carboxylic ring. In order to improve 
sensitivity, electrospray ionization in the negative 
mode [ESI-] could be used for MS/ MS detection of 
RSV in plasma that produced abundant deprotonated 
molecule [M-H-] at m/z 480 as demonstrated by Gao 
et al. Retention times were very short, including 
methods for simultaneous analysis with other drugs, 
ranging from 0.9 minutes up to 4.1 minutes. Isocratic 
elution was applied in most cases. More sensitive 
methods have been developed using LC–MS/MS with 
linearity ranging from 0.02 ng/mL to 512 ng/mL. A 
method using LC-MS/MS equipped with an ESI 
interface and operated in -ve ionization mode was 
employed with this aim contrast to the most usual 
method that uses positive ionization mode for RSV 
detection. RSV retention time was 4.18 minutes, and 
the final analysis eluted at 4.95 minutes. Kosek et al. 
recently reported a sensitive LC - MS / MS method to 
quantify all statins in human plasma simultaneously. 
The mass spectrometry was conducted in negative ion 
electrospray mode for RSV determination and it 
showed retention time at 3.08 minutes and the lower 
concentration in the linearity range of 0.4 ng/mL. 
 
Gandla et al. LC - MS / MS technique for RSV 
resolution in human plasma was studied and certified. 
RSV d6 has been used as an internal standard [IS]. The 
method employs lesser plasma volume [100 μL] 
processed by simple solid-phase extraction [SPE] 
procedure. This method possesses a suitable degree of 
precision and accuracy in accordance with US FDA 
guidelines. The runtime was also set at 2 min, which 
is fast and more samples can be studied in a day. This 
analytical method can be obliging for estimating the 
pharmacokinetics of oral RSV for a pharmacokinetic 
or bioavailability/bioequivalence studies[41]. Bai X et 
al. has developed rapid and susceptible ultra-
performance liquid chromatography-tandem mass 
spectrometry [UPLC-MS/MS] assay was established 
and certified for the simultaneous quantification of 
RSV, RSV-5 S-lactone [RSV-LAC], and N-desmethyl 
RSV in human plasma. Mass spectrometry detection 
was performed through positive ion electrospray 
ionization [ESI][42]. Kumar et al. were developed 
LC-MS / MS technique for simultaneous resolution of 
RSV and metformin [MET] in human plasma. Simple 
protein precipitation with acetonitrile [ACN] involved 
the assay procedure. The portion of supernatant was 
transferred after precipitation and vaporized under a 
mild flux of nitrogen [40°C]. The mobile phase residue 
was reconstituted and injected[43].B. Siddartha et al. 
has reported the LC-MS/MS method stands validated 
and is suitable for estimation of plasma RSV 
concentrations as a single analytical run, in clinical 
samples from Bioequivalence studies following oral 
administration of RSV fixed dose [5/10/20mg] tablets 
in healthy human subjects[44].A. Narapusetti et al. 
established and certified a rapid, selective and 
sensitive LC - MS / MS method in MRM mode to 
determine RSV and amlodipine [AML] in human 
plasma simultaneously. The proposed technique was 
fast with a 2.5 min of chromatographic run time and 
simultaneously suitable for high - performance 
bioanalysis of RSV and AML. In addition, the method 
demonstrated suitability for human clinical studies. 
Furthermore, the sample reanalysis incurred 
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effectively proves that the assay is 
reproducible[45].Varghese and Ravi studied 
simultaneous quantitation of RSV and ezetimibe 
[EZE] in biological fluid [human plasma] by LC-
ESI/MS method Selected ion observing using their 
particular [M-H] - ions, m/z 480, m/z 408, and m/z 557 
respectively for RSV, EZE and Atorvastatin [ATV] as 
IS was performed on a mass spectrometer. This 
method was used for pharmacokinetic, bioavailability, 
or bioequivalent studies of RSV and EZE in human 
plasma[48].R.K. Trivedi et al. has reported validated 
LC-MS/MS described herein for the simultaneous 
estimation of RSV and fenofibric acid [FEA] in human 
plasma is specific, accurate, precise and reproducible. 
In addition, the present technique utilizes a single step 
liquid/ liquid extraction technique with a 
commercially available IS. The assay was positively 
applied in a clinical pharmacokinetic study to 
simultaneously determine the concentration - time 
profiles of RSV and FEA[59]. C.K. Hull et al. has 
reported sensitive, accurate, reproducible and specific 
LC-MS/MS technique for the quantification of RSV in 
human plasma. With a 0.1 ng/ml lover limit of 
quantification [LLOQ], the desired sensitivity for RSV 
was achieved. When stored at -220 and -270 ° C, RSV 
was shown to be stable in routine analytical conditions 
and human plasma and buffered plasma for up to 6 
months. A number of thousands of human plasma 
samples from a series of human RSV clinical studies 
were successfully analyzed using the method[60]. 
 
CAPILLARY ELECTROPHORESIS-MASS 
SPECTROSCOPY: 
Mohemad Dowod et al. has studied method with the 
EOF reversal agent, polybrene, in monoammonium 
carbonate electrolyte, pH 9.00. The ionic power and 
the quantity of MeOH in buffer were optimized in a 
multivariate manner use of artificial neural complexes, 
with optimum conditions being 60mM 
monoammonium carbonate containing 60 percent 
MeOH, providing baseline determination within 20 
min of the five hypolipidaemics. Using electrokinetic 
supercharging, the sensitivity of the technique was 
1000-fold improved over conventional injections 
under field-amplified fraction stacking conditions with 
180 ng / L LODs. This is the 1st report of CE 
separation of hypolipidaemics[Pravastatin, 
Fluvastatin, Atorvastatin, gemfibrozil, Rosuvastatin]. 
The method was validated and then applicable to the 
determination of objective drugs in water fractions 
from Hobart city[61]. 
 
GAS CHROMATOGRAPHY-MASS 
SPECTROSCOPY: 
B. H. Woollen et al. has explained study of 3,5-
Dihydroxy-3-methylvaleric acid [MVA] in human 
urine including transformation to MVA lactone 
[MVAL] and examination by GC-MS. A strategy was 
explained to achieve a low limit of quantitation to 
overcome the constraint that calibration must be 
executed in urine [since MVAL is adsorbed in the 
absence of matrix] and control urine every time 
contains significant amounts of MVA. Information are 
presented for authentication of the technique over the 
range 75-300 ng mL-1 and for application of the 
method to a clinical studied with the drug 
rosuvastatin[62].Ali Ismail et al. determined the 
residual solvents present in some statins. A selective 
Gas chromatography with headspace and Mass 
Spectrometer detectors [HS-GC-MS] has been 
developed and validated according to different aspect 
of validation as per ICH. The method has been found 
to be simple, sensitive, rugged, reliable and 
reproducible for the quantitation of n-hexane and 
ethanol widely used during synthesizing of 
atorvastatin and rosuvastatin or formulating into 
dosage form. The limit of detection was calculated to 
be 2.53 ppm and 1.63 ppm per sample for ethanol and 
n-hexane, respectively. Limit of quantification was 
7.59 ppm ethanol, LOQ= 4.89 ppm for n-Hexane. 
Correlation factor was 0.999 for both ethanol and n-
hexane. The percentage recovery was calculated and 
the value was 99.29 % and 96.01% for ethanol and n- 
hexane, respectively. The total run is 16 minutes[63].  
 
LIQUID CHROMATOGRAPHY-NUCLEAR 
MAGNETIC RESONANCE: 
Shahu A. et al. studied forced degradation behavior 
of rosuvastatin under conditions prescribed by ICH. 
Under acid hydrolytic and photolytic circumstances, 
the drug was originated to be labile, while base / 
neutral hydrolytic, oxidative and thermal stress was 
stable. A total of 11 degradant were prepared, 
performed on a C-18 column with a stability-
indicating technique. LC-MS analyzes specified that 
five degradation products had the similar molecular 
mass as the drug, while the remains six had 18 Da less 
than the drug. Structural elucidation of all the 
degradant products was performed with the help of 
sophisticated and modern structural description tools, 
viz. LC-MS/TOF, LC-MS, on-line H / D exchange and 
Liquid Chromatography-NMR. The drug’s 
mechanisms of degradation and degradation pathway 
were delineated. In addition, toxicity in-silico was 
predicted and equaled with the drug for all degradation 
products with the help of DEREK and TOPKAT 
software[64]. 
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CONCLUSIONS: 
The present review article gives the comprehensive 
details about LC-MS/MS, CE-MS, GC-MS, LC-NMR 
methods applied for the analysis of RSV in 
pharmaceutical formulation and various biological 
matrices. Most of these validated hyphenated methods 
are specific, sensitive, reproducible and accurate. 
These bioanalytical methods are support to estimation 
of pharmacokinetic or bioavailability or 
Bioequivalence studies of oral solid dosage form 
containing RSV. In this review, the bioanalytical data 
support the utility of the methods for therapeutic drug 
monitoring and also for routine chemical sample 
analysis with desired analogues. 
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Figure 1. Chemical structure of rosuvastatin calcium 
Chemical formula- 
C44H54CaF2N6O12S2 
Molecular weight- 
1001.141 g/mol 
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TABLE 1- LIQUID CHROMATOGRAPHY-MASS SPECTROSCOPY 
Drug Matrices Interface Extraction method Column 
& 
 Mobile Phase 
Flow 
Rate 
[ml/min] 
Rt 
[min] 
Linearity 
range 
LLOQ 
 
Reference 
2017 
RSV Human 
plasma 
Turboionspray 
[ESI] 
Simple solid phase extraction 
method, Rosuvastatin d6 as 
internal standard 
Discovery HS C18 
[50 mm×4.6 mm, 5μm] column 
& 
 Ammonium acetate [5mM, pH 
3.5]: acetonitrile  
[20:80, v/v] 
0.7 0.85 0.51-100.9 
ng/mL 
0.51  
ng/mL 
 
41 
RSV 
& 
RSV-LAC 
& 
N-
Desmethyl 
RSV 
Human 
plasma 
ESI Liquid-liquid extraction 
with ethyl acetate from 100 μL 
acidulated buffered plasma 
Acquity UPLC HSS T3 column  
[100 mm×3.0 mm, 1.8 μm] 
& 
0.1 % gradient formic acid [A]:  
acetonitrile [solvent B] in 
gradient elution 
0.3 
 
2.69 
& 
3.10 
& 
2.33 
0.1-50 
ng/ml 
& 
0.2-100 
ng/ml 
0.1 ng/ml 
& 
0.2 ng/ml 
42 
2015 
RVS 
& 
MET 
Human 
plasma 
ESI fortified postextracted sample Thermo Hypurity C18column  
[50 mm×4.6 mm, 5 μm] 
& 
0.1% v/v formic acid in water: 
acetonitrile [30:70 v/v] 
 
0.4 
 
2.01 
& 
1.43 
0.5-200 
ng/mL 
& 
2-2000 
ng/mL 
0.5 
ng/mL 
& 
2 ng/mL 
43 
2014 
RSV Human 
plasma 
Turboionspray Solid Phase Extraction;  
and extracted from human 
plasma 
C18 column  
[50 mm×4.6 mm, 3 μm] 
& 
 Acetonitrile: 10 mM 
ammonium acetate at pH 3.1 
[55:45 v/v] 
1 1.34 0.5-512 
ng/mL 
0.5 
ng/mL 
44 
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RSV 
& 
AML 
Human 
plasma 
Turboionspray 
at 550 ̊C 
Liquid-liquid extraction 
using a mixture of ethyl acetate 
and n-hexane [80:20, v/v] 
Zorbax SB C18 column [50 
mm×4.6 mm, 3.5 μm ] 
& 
0.1% formic acid in 5 mM 
ammonium acetate: methanol: 
acetonitrile [20:20:60 v/v/v] 
0.75 1.30 
& 
1.7 
0.52-51.77 
ng/mL 
& 
0.10-10.07 
ng/mL 
0.52 
ng/mL 
& 
0.10 
ng/mL 
45 
RSV 
& 
N-
Desmethyl 
RSV 
Human 
plasma 
ESI Liquid-liquid extraction using 
acetonitrile 
HiChrom C18 [150mm×3.0mm, 
3 μm] 
& 
0.1% formic acid in acetonitrile: 
0.1 % formic acid in water 
[70:30 v/v] 
0.3 3.38 
& 
2.64 
0.2-20 
ng/mL 
& 
0.1-10 
ng/mL 
0.1,0.2 
ng/mL 
& 
0.03, 
0.1 
ng/mL 
 
46 
2013 
RSV 
& 
N-
Desmethyl 
RSV 
Human 
plasma 
ESI Liquid-liquid extraction using 
diethyl ether 
X-Terra MS C-18 column 
[50 mm×4.6mm, 5.0 μm] 
& 
15 μmol/L ammonium acetate in 
water [solution A] and in 
methanol 
[Solution B], adjusted to pH 6 
with aqueous ammonia [2 
mol/L] 
0.4 5.061 
& 
4.226 
0.05-42 
μg/mL 
& 
0.02-14 
ng/mL 
0.05 
μg/mL 
& 
0.02 
μg/mL 
47 
RSV 
& 
EZE 
Human 
plasma 
ESI Liquid-liquid extraction, 
atorvastatin as internal standard 
Luna C18 column [150×4.60 
mm, 5 μm] 
& 
0.1% [v/v] formic acid: 
methanol [20:80 v/v] 
1 2.7 
& 
3.4 
0.1-10 
ng/mL 
0.10 
ng/mL 
48 
2011 
RSV Human 
plasma 
ESI Liquid-liquid extraction  and 
solid-phase extraction and 
extracted with ethyl acetate 
Diamonsil C18 column [150 
mm×4.6 mm,5 mm] 
& 
Acetonitrile: Methanoic acid 
[0.1%] [60:40 v/v] 
0.8 3 .0 0.1-60  
ng/mL 
0.1 
ng/mL 
49 
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RSV Tablet ESI Solid-phase extraction and 
extracted with methanol 
C8 [50 mm×4.6 mm, 5μm] 
& 
0.2% acetic acid: methanol 
[60:40 v/v] 
0.3 6.5 1–6 μg/mL 1 μg/mL 50 
RSV 
& 
RSV-LAC 
& 
N-
Desmethyl 
RSV 
Human 
plasma 
ESI Liquid-liquid and solid-phase 
extractions and extracted from 
50 μL of buffered human 
plasma by protein precipitation 
Zorbax-SB Phenyl column 
[100 mm×2.1 mm, 3.5 μm] 
& 
0.1% v/v glacial acetic acid in 
10% v/v methanol in water 
[solvent A] and 40% v/v 
methanol in Acetonitrile 
[solvent B] 
0.35 3.3 
& 
2.8 
& 
3.8 
0.1-100 
ng/mL 
DM-RSV- 
0.5-100 
μg/mL 
0.1 
ng/mL 
DM-
RST-0.5 
51 
2009 
RSV Human 
plasma 
Turboionspray Automated liquid-liquid 
extraction 
Symmetry shield RP18 column 
[50mm×4.6 mm,3.5 μm]  
& 
A:Water: methanol  
[35:65 v/v]; 
ammonium formate 5mM; 
B: 100% methanol, gradient 
elution 
1 0.90 50-25000 
pg/ml 
100 
pg/ml 
52 
2007 
RSV Human 
plasma 
Turboionspray 
475 ̊C 
solid-phase extraction and 
internal standard from plasma 
with acetonitrile 
Inertsil ODS 3 column [100mm 
× 4.6mm, 3.0 μm] 
& 
0.05 mol/L formic acid: 
acetonitrile [20:80 v/v] 
0.5 1.8 0.5-50 
ng/mL 
1 ng/mL 
 
53 
RSV Human 
plasma 
Turboionspray 
[ESI] 
liquid–liquid extraction with 
ethyl ether 
Zorbax XDB-C18 
[150mm×4.6mm, 5 μm] column  
& 
methanol–water [75:25v/v] 
adjusted to pH 6 by aqueous 
ammonia 
0.5 2.36 0.02-60 
ng/mL 
0.02 
ng/mL 
54 
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Abbreviation: RSV-LAC: RSV-5S-lactone; MET: metformin; AML: amlodipine; EZE: ezetimibe; FEA: fenofibric acid; ESI: electrospray ionization; Rt: 
retention time; LLOQ: lower limit of quantification 
 
RSV Human 
plasma 
ESI Liquid-liquid extraction, 
Internal standard estrone 
Phenomenex Luna C18 5μm 
[150 mm×4.6mm] 
& 
2% formic acid: methanol  
[20:80 v/v] 
1 2.3 0.1-20 
ng/mL 
0.1 
ng/mL 
55 
2006 
RSV Human 
plasma 
ESI Liquid-liquid extraction internal 
standard Cilostazol extracted 
with ether 
Atlantis C18 column 
[150mm×2.1mm, 5.0 μm] 
& 
0.2% formic acid: methanol 
[30:70 v/v] 
0.2 4.13 0.2-50 
ng/mL 
0.2 
ng/mL 
56 
RSV Human 
plasma 
Turboionspray 
 
Solid-phase extraction Microbore columns packed with 
Luna C18 [5cm×2.0, 1.0 and 0.5 
mm]3μm  
& 
Methanol: water [7:3 v/v] with 
0.2% [v/v] formic acid 
0.06 1.8 0.05-50 
ng/mL 
0.05 
ng/mL 
57 
2005 
RSV Human 
plasma 
 Solid phase extraction YMC J’ Sphere ODS H-80 
column[150 mm×4.6 mm, 4.0 
μm] & 
0.2% formic acid in Water: 
acetonitrile [40: 60 v/v] 
1 2.5 1-50 
ng/mL 
0.25 
ng/mL to 
100 μL 
58 
RSV 
& 
FEA 
Human 
plasma 
Turboionspray 
At 400 ̊C 
Liquid-liquid extraction, 
 Carbamazepine as internal 
standard from plasma into ethyl 
acetate 
X-Terra MS C-18 column 
[50 mm×4.6mm, 5.0 μm] 
& 
0.05M formic acid: acetonitrile 
[45:55 v/v] 
0.4 2.35 
& 
4.70 
1-50 
μg/mL 
 
1 μg/mL 59 
2002 
RSV Human 
plasma 
Turboionspray  Automated solid-phase 
extraction 
Luna C18  
[150 mm×4.6 mm,5 μm] 
& 
 Methanol: 0.2% formic 
acid in water [70:30 v/v] 
1 3.63 0.1-30 
ng/mL 
0.1 
ng/mL 
60 
